Abstract
Human respiratory syncytial virus (hRSV) is the leading cause of severe lower respiratory tract infections in children. The development of novel prophylactic and therapeutic antiviral drugs against hRSV is imperative to control the burden of disease in the susceptible population. In this study, we examined the effects of inducing the activity of the host enzyme heme oxygenase-1 (HO-1) on hRSV replication and pathogenesis on lung inflammation induced by this virus. Our results show that after hRSV infection, HO-1 induction with metalloporphyrin cobalt protoporphyrin IX significantly reduces the loss of body weight due to hRSV-induced disease. Further, HO-1 induction also decreased viral replication and lung inflammation, as evidenced by a reduced neutrophil infiltration into the airways, with diminished cytokine and chemokine production and reduced T cell function. Concomitantly, upon cobalt protoporphyrin IX treatment, there is a significant upregulation in the production of IFN-α/β mRNAs in the lungs. Furthermore, similar antiviral and protective effects occur by inducing the expression of human HO-1 in MHC class II+ cells in transgenic mice. Finally, in vitro data suggest that HO-1 induction can modulate the susceptibility of cells, especially the airway epithelial cells, to hRSV infection.
Footnotes
This work was supported by grants from Comisión Nacional de Investigación Científica y Tecnológica/Fondo Nacional de Desarrollo Científico y Tecnológico (Postdoctorado 3140455, 1140011 and 1150862), Instituto Milenio en Inmunología e Inmunoterapia (P09-016-F). J.A.E. and R.S.G. are Comisión Nacional de Investigación Científica y Tecnológica de Chile Fellows.
The online version of this article contains supplemental material.
Abbreviations used in this article:
- BALF
- bronchoalveolar lavage fluid
- CoPP
- cobalt protoporphyrin IX
- ΔΔ Ct
- ΔΔ threshold cycle
- DC
- dendritic cell
- DOX
- doxycycline
- HCV
- hepatitis C virus
- HEp-2
- human laryngeal epidermoid carcinoma number 2
- HO-1
- heme oxygenase-1
- hRSV
- human respiratory syncytial virus
- LM
- littermate
- LRTI
- lower respiratory tract illness
- MHC-II
- MHC class II
- MHC-II−
- MHC-II negative
- MHC-II+
- MHC class II positive
- MOI
- multiplicity of infection
- N
- nucleoprotein
- qPCR
- quantitative PCR
- SnPP
- tin protoporphyrin IX dichloride
- UT
- untreated.
- Received August 15, 2016.
- Accepted April 24, 2017.
- Copyright © 2017 by The American Association of Immunologists, Inc.